Scoop has an Ethical Paywall
Roche Position Statement Regarding Herceptin
14 February 2006
Roche Position Statement Regarding Herceptin
Roche Products (NZ) Limited is working proactively and constructively with both Medsafe and Pharmac to ensure the fastest possible access to Herceptin for HER2 positive women with early breast cancer in New Zealand. The regulatory submission to permit the extension of licensed use of Herceptin for early breast cancer was submitted to Medsafe in November.
The clinical evidence dossier required as part of the reimbursement process for Herceptin in early stage disease was submitted to Pharmac in December.
We are currently completing an additional dossier for Pharmac to demonstrate the cost-effectiveness of Herceptin in this setting and aim to have this completed by early March. Roche cannot speculate on the expected timelines these processes may take, but we commit to responding as promptly as possible to any additional requests for information that either agency may require as part of their assessment process.
ENDS
NZ Society for the Study of Diabetes: Critical Workforce Shortages Leave People With Type 1 Diabetes Unable To Access Life Changing Technology
Kindergartens Aotearoa: Kindergartens Aotearoa Opposes Lower Standards For Homebased Services
Universities New Zealand - Te Pokai Tara: Three Outstanding Aotearoa New Zealand Students Awarded Rhodes Scholarships
University of Auckland: 800 Mathematicians Set To Converge On Auckland
NZEI Te Riu Roa: NZEI Te Riu Roa Joins Calls To Restore Cut To Pasifika Early Literacy Project
NZ Opera: New Zealand Opera To Celebrate 25 Years In 2025